Pricing & Access· July 13, 2026 · 20 min read
ATTR-CM Access Landscape: Tafamidis, Acoramidis, and Vutrisiran
By Ran Chen#Rare Disease#Payer Coverage#Payer Criteria
Topic
Payer Coverage
Plan coverage status, preferred products, restriction patterns, and payer-policy changes that affect access.
Pricing & Access· July 12, 2026 · 20 min read
Lupus and SLE Access: Benlysta, Saphnelo, Lupkynis, and Autoimmune CAR-T
By Ran Chen#Payer Coverage#Payer Criteria#CAR-T
Pricing & Access· July 12, 2026 · 20 min read
Severe Asthma Biologics: Access and Phenotype Matching Guide
By Ran Chen#Payer Coverage#Payer Criteria#Respiratory
Specialty· July 11, 2026 · 16 min read
Hemophilia Access 2026: Prophylaxis and Gene Therapy Post-Roctavian
By Ran Chen#Gene Therapy#Hematology#Payer Coverage
Pricing & Access· July 11, 2026 · 16 min read
Sanofi Portfolio Dossier: Dupixent Growth, Lantus Cliff, and Altuviiio Pivot
By Ran Chen#Immunology#Orange Book#Purple Book
Pricing & Access· July 9, 2026 · 18 min read
AbbVie Portfolio Dossier: Skyrizi, Rinvoq, and 2030s Patent Cliffs
By Ran Chen#Immunology#Orange Book#Purple Book
Pricing & Access· July 1, 2026 · 17 min read
CDK4/6 Inhibitor Access Landscape: Payer Dynamics After Ibrance's Expansion
By Ran Chen#Oncology#Breast Cancer#Payer Coverage
Generics· June 21, 2026 · 5 min read
Generic Contrast Media: Amneal's Iohexol CGT Exclusivity and Shortage Triage
By Ran Chen#Generics#Orange Book#Manufacturing Capacity
Policy· June 14, 2026 · 12 min read
How to read an FDA drug label on DailyMed: indication scope, boxed warnings, and PA
Biosimilars· June 7, 2026 · 8 min read